334 related articles for article (PubMed ID: 32169477)
1. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Jamme P; Fernandes M; Copin MC; Descarpentries C; Escande F; Morabito A; Grégoire V; Jamme M; Baldacci S; Tulasne D; Kherrouche Z; Cortot AB
J Thorac Oncol; 2020 May; 15(5):741-751. PubMed ID: 32169477
[TBL] [Abstract][Full Text] [Related]
2. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
[TBL] [Abstract][Full Text] [Related]
5. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
6. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
Front Oncol; 2021; 11():649766. PubMed ID: 34249687
[TBL] [Abstract][Full Text] [Related]
8. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
11. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
12. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Fujino T; Kobayashi Y; Suda K; Koga T; Nishino M; Ohara S; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2019 Oct; 14(10):1753-1765. PubMed ID: 31279006
[TBL] [Abstract][Full Text] [Related]
14. Met inhibitors in the treatment of lung cancer: the evidence to date.
Hamilton G; Rath B
Expert Opin Pharmacother; 2022 May; 23(7):815-825. PubMed ID: 35377279
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
16. MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Fernandes M; Hoggard B; Jamme P; Paget S; Truong MJ; Grégoire V; Vinchent A; Descarpentries C; Morabito A; Stanislovas J; Farage E; Meneboo JP; Sebda S; Bouchekioua-Bouzaghou K; Nollet M; Humez S; Perera T; Fromme P; Grumolato L; Figeac M; Copin MC; Tulasne D; Cortot AB; Kermorgant S; Kherrouche Z
Mol Oncol; 2023 Nov; 17(11):2257-2274. PubMed ID: 36799689
[TBL] [Abstract][Full Text] [Related]
17. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
18. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
20. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH
Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
